Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Presenting at Cowen Healthcare Conference

8 Mar 2018 07:00

RNS Number : 0452H
Realm Therapeutics PLC
08 March 2018
 

Realm Therapeutics to Present at the Cowen and Company 38th Annual Health Care Conference

 

MALVERN, PA, March 8 2018 - Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, announced today that Alex Martin, CEO, will be presenting at the Cowen and Company 38th Annual Health Care Conference, on Tuesday, March 13, 2018 at 10:00 a.m. ET at the Boston Marriott Copley Place. 

 

A live and archived webcast of the Cowen presentation will be available on the Events and Presentations page of the Company's website. An updated copy of Realm's corporate presentation will be available on March 13 on the Company's website at www.realmtx.com

 

About Realm Therapeutics

 

Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that target the intersection between innate and adaptive immunity, to influence immune signaling and to change the course of immune-mediated diseases in adults and children. Realm's lead drug development programs utilize the Company's proprietary immunomodulatory technology for the treatment of Allergic Conjunctivitis (PR013) and Atopic Dermatitis (PR022) and Realm is exploring its efficacy in Acne and additional Dermatology and Ophthalmology indications as well as other disease areas. For more information on Realm Therapeutics, Inc. please visit www.realmtx.com.

 

Forward Looking Statements

 

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

 

Contact:

Realm Therapeutics plc

Alex Martin, Chief Executive Officer

Marella Thorell, Chief Financial Officer and Chief Operating Officer

Outside US: +44 (0) 20 3727 1000

US: +1 212 600 1902

 

Argot Partners

Stephanie Marks

+1 212 600 1902

 

FTI Consulting

Simon Conway / Mo Noonan

+44 (0) 20 3727 1000

 

N+1 Singer (Nominated Adviser and Broker) Aubrey Powell / Jen Boorer

+44 (0) 20 7496 3000

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAEAPDXELAPEFF
Date   Source Headline
2nd Nov 20097:00 amRNSDarren Weiss promoted to CFO & Executive Director
15th Sep 20099:47 amRNSHolding(s) in Company
2nd Sep 20092:32 pmRNSHolding(s) in Company
27th Aug 20097:00 amRNSTotal Voting Rights
25th Aug 20094:18 pmRNSHolding(s) in Company
25th Aug 20097:00 amRNSInterim Results
25th Aug 20097:00 amRNSPuriCore New $2.1 Million Facility
5th Aug 20097:00 amRNSTrading Statement
5th Aug 20097:00 amRNSAcquisition and Placing
4th Aug 20097:00 amRNSBlocklisting Interim Review
24th Jul 20094:40 pmRNSSecond Price Monitoring Extn
24th Jul 20094:35 pmRNSPrice Monitoring Extension
10th Jul 20094:40 pmRNSSecond Price Monitoring Extn
10th Jul 20094:35 pmRNSPrice Monitoring Extension
7th Jul 20094:40 pmRNSSecond Price Monitoring Extn
7th Jul 20094:35 pmRNSPrice Monitoring Extension
17th Jun 20097:00 amRNSPresenting at Piper Jaffray European Conference
5th Jun 200911:20 amRNSResult of AGM
28th May 20091:16 pmRNSUS retailer extends use of Sterilox systems
27th May 20097:00 amRNSAnnual Information Update
30th Apr 20095:01 pmRNSHolding(s) in Company
30th Apr 20097:00 amRNSSterilox Effective against Human/Animal Influenza
28th Apr 20097:01 amRNSQ1 Interim Management Statement
28th Apr 20097:00 amRNSFinal Results
17th Feb 200910:45 amRNSHolding(s) in Company
10th Feb 20094:28 pmRNSDirector/PDMR Shareholding
9th Feb 20097:00 amRNSDirector/PDMR Shareholding
6th Feb 200910:27 amRNSHolding(s) in Company
4th Feb 20099:28 amRNSBlocklisting Interim Review
3rd Feb 20099:41 amRNSDirector/PDMR Shareholding
2nd Feb 20097:00 amRNSTrading Statement
2nd Jan 20097:00 amRNSDirector/PDMR Shareholding
29th Dec 20084:34 pmRNSDirector/PDMR Shareholding
19th Dec 20084:43 pmRNSSecond Price Monitoring Extn
19th Dec 20084:36 pmRNSPrice Monitoring Extension
12th Nov 20085:01 pmRNSDirector/PDMR Shareholding
3rd Nov 20087:00 amRNSNotification of PDMR Interest - Option Award
24th Oct 20087:00 amRNSReceives an order from Safeway
13th Oct 20087:01 amRNSBoard and Organisational Changes
13th Oct 20087:00 amRNSInterim Management Statement
1st Oct 20087:00 amRNSRaises $9.74 million
11th Sep 20085:51 pmRNSHolding(s) in Company
4th Sep 20085:51 pmRNSHolding(s) in Company
3rd Sep 20085:26 pmRNSHolding(s) in Company
29th Aug 20082:44 pmRNSPDMR Dealings
29th Aug 20087:00 amRNSTotal Voting Rights
29th Aug 20087:00 amRNSInterim Results
26th Aug 20083:02 pmRNSResult of General Meeting
22nd Aug 20087:00 amRNSResult of Open Offer
4th Aug 20088:27 amRNSBlocklisting six monthly retu

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.